<DOC>
	<DOCNO>NCT01979965</DOCNO>
	<brief_summary>The purpose study find whether mitral regurgitation ( leaky heart valve ) cause ischemic heart disease ( decreased blood flow heart muscle ) improve administration ranolazine .</brief_summary>
	<brief_title>Effect Ranolazine Valvular Disease Patients With Pacemakers</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Ischemic cardiomyopathy AND Moderate severe mitral regurgitation AND Cardiac resynchronization therapy ( CRT ) ≥ 3 month prior enrollment AND Maximal Medical Therapy ( ACEInhibitor , beta blocker , aldosterone antagonist , diuretic , aspirin , statin ) nonischemic cardiomyopathy active heart failure current ranolazine therapy congenital heart disease mechanical valve prosthesis vegetation/endocarditis significant pulmonary disease peripheral vascular disease trivial mild mitral regurgitation creatinine clearance &lt; 30 mL/min liver cirrhosis strong inhibitor CYP3A ( include ketoconazole , itraconazole , clarithromycin , nefazodone , nelfinavir , ritonavir , indinavir , saquinavir ) strong inducer CYP3A ( include rifampin , rifapentine , phenobarbital , phenytoin , carbamazepine St.John 's wort ) Strong Pglycoprotein inhibitor ( include cyclosporine , verapamil , quinidine ) Initial QTc interval ≥ 440msec</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>cardiac resynchronization therapy</keyword>
	<keyword>ranolazine</keyword>
	<keyword>maximal medical therapy</keyword>
	<keyword>ischemic cardiomyopathy</keyword>
</DOC>